New hope for kids battling tough leukemia: experimental drug combo enters first human trial
NCT ID NCT06466395
Summary
This study aims to find a safe and effective dose of a two-drug combination (Hyper-CVAD and venetoclax) for children and young adults whose leukemia has returned or not responded to standard treatments. It will enroll up to 22 participants aged 2 to 21 years old. The main goal is to determine the safest dose and see how well the body tolerates this new treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNDIFFERENTIATED LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.